TY - JOUR
T1 - Autonomic dysfunction in early breast cancer
T2 - Incidence, clinical importance, and underlying mechanisms
AU - Lakoski, Susan G.
AU - Jones, Lee W.
AU - Krone, Ronald J.
AU - Stein, Phyllis K.
AU - Scott, Jessica M.
N1 - Funding Information:
This work is supported in part by the National Institute of General Medical Sciences/National Institutes of Health ( P20GM103644-01A1 ). The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper, and its final contents.
Publisher Copyright:
© 2015 Elsevier Inc. All rights reserved.
PY - 2015/8/1
Y1 - 2015/8/1
N2 - Autonomic dysfunction represents a loss of normal autonomic control of the cardiovascular system associated with both sympathetic nervous system overdrive and reduced efficacy of the parasympathetic nervous system. Autonomic dysfunction is a strong predictor of future coronary heart disease, vascular disease, and sudden cardiac death. In the current review, we will discuss the clinical importance of autonomic dysfunction as a cardiovascular risk marker among breast cancer patients. We will review the effects of antineoplastic therapy on autonomic function, as well as discuss secondary exposures, such as psychological stress, sleep disturbances, weight gain/metabolic derangements, and loss of cardiorespiratory fitness, which may negatively impact autonomic function in breast cancer patients. Lastly, we review potential strategies to improve autonomic function in this population. The perspective can help guide new therapeutic interventions to promote longevity and cardiovascular health among breast cancer survivors.
AB - Autonomic dysfunction represents a loss of normal autonomic control of the cardiovascular system associated with both sympathetic nervous system overdrive and reduced efficacy of the parasympathetic nervous system. Autonomic dysfunction is a strong predictor of future coronary heart disease, vascular disease, and sudden cardiac death. In the current review, we will discuss the clinical importance of autonomic dysfunction as a cardiovascular risk marker among breast cancer patients. We will review the effects of antineoplastic therapy on autonomic function, as well as discuss secondary exposures, such as psychological stress, sleep disturbances, weight gain/metabolic derangements, and loss of cardiorespiratory fitness, which may negatively impact autonomic function in breast cancer patients. Lastly, we review potential strategies to improve autonomic function in this population. The perspective can help guide new therapeutic interventions to promote longevity and cardiovascular health among breast cancer survivors.
UR - http://www.scopus.com/inward/record.url?scp=84939490250&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2015.05.014
DO - 10.1016/j.ahj.2015.05.014
M3 - Review article
C2 - 26299219
AN - SCOPUS:84939490250
SN - 0002-8703
VL - 170
SP - 231
EP - 241
JO - American heart journal
JF - American heart journal
IS - 2
ER -